Sign In
NewsRadar

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.

   


Peter Keen appointed to the Prelude Trust Board


PRELUDE TRUST PLC

Board Appointment

Prelude Trust plc (“Prelude” or “the Trust”), the investment trust managed by Esprit Capital Management Ltd (“Esprit”) that specialises in high growth technology-based businesses, is pleased to announce that Peter Keen has been appointed to the Board with effect from 1 August 2007.

Peter who is a Partner at Esprit Capital Partners LLP comes to the Board with over 23 years experience in both management and investing in technology and life science businesses. Having trained as a chartered accountant with Arthur Young (now Ernst & Young), he spent 12 years in the healthcare and biotechnology industries with Agricultural Genetics Ltd, Cambridge Life Sciences plc and Chiroscience Group plc. He was a co-founder of Chiroscience having been part of the original venture backed buyout and was responsible for its IPO in 1994. In 1996, he co-founded the life sciences venture capital firm Merlin Biosciences, where he was UK Managing Director until early 2003 and prior to joining Esprit last year he was Chief Financial Officer of Arakis Ltd where he led a refinancing and a successful £106m trade sale, having been responsible at Merlin for the original seed investment.

In 1997 he was involved in the launch of an investment trust the Biotech Growth Trust plc where he remains a non-executive director and he is also a non executive director of Abcam plc and Ark Therapeutics Group plc.

Commenting on the appointment Mike Brooke, Chairman of Prelude said: “I am delighted that Peter is joining our Board, he has been an invaluable member of the Prelude team since joining in November last year. Peter is an asset to the Trust, bringing with him the perfect mix of experience, combining technology and life science venture capital funding, with publicly listed vehicles and an array of financial management roles. I look forward to working alongside Peter and welcome his contribution to the Board.”

Director Declaration

The following information is given in accordance with paragraph 9.6.13 of the Listing Rules:-

Peter Keen is currently a director of the following publicly quoted companies:
Ark Therapeutics plc
Abcam plc
The Biotech Growth Trust plc (Formerly Finsbury Emerging Biotechnology plc)

Peter Keen has held the following directorships in publicly quoted companies in the past five years of which he is no longer a director:
BioProgress plc
ReNeuron Holdings plc

There are no further disclosures to be made pursuant to paragraph 9.6.13 of the Listing Rules.
The Company has been advised that Peter Keen does not have a beneficial interest in shares of the Company.

For further information, please visit www.prelude-trust.co.uk or contact:

Peter Keen/Jayne Tamblin John West/Clemmie Carr
Prelude Trust plc Tavistock Communications
Tel: 01223 307 770 Tel: 020 7920 3150
peter.keen@espritcp.com jwest@tavistock.co.uk

-Ends-


Publisher Contact Information:

Prelude Trust
+44 1223 307 770
peter.keen@espritcp.com

Company profile of DFJ Esprit (formerly Prelude Ventures Ltd.)
Past press releases of DFJ Esprit (formerly Prelude Ventures Ltd.).

Data


26,227
Tech investments
From our Online Data Service
16,943
VC-backed companies
From our Radar


Recent Deals


DATEAMOUNTSECTOR
Oct 11N/AInternet services
Oct 11€1.1MKnowledge management
Oct 11N/AInternet services
Oct 11€13.0MBiotechnology
Oct 11N/AMedical devices
Oct 10€50.0MInternet services
Oct 10€23.0MOther Computers & Electronics

For information on Europe's most extensive database on technology funding click here!

Events



Press Releases


May 28
Identiq
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
Nethone
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...





About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.